Pyrrolobenzodiazepine

Pyrrolobenzodiazepine

Pyrrolobenzodiazepine (PBD) is a class of antibiotics that are known for their DNA-binding properties. These compounds are derived from natural sources and have been extensively studied for their potential use in cancer therapy.

History

Pyrrolobenzodiazepines were first isolated in the 1960s from the cultures of Streptomyces species. The initial compounds discovered were anthramycin and sibiromycin, which exhibited potent antitumor activity. This led to further research into the class and the development of synthetic analogs.

Structure and Properties

Pyrrolobenzodiazepines are characterized by a tricyclic structure that includes a pyrrole ring, a benzene ring, and a diazepine ring. The diazepine ring is a seven-membered ring with two nitrogen atoms. This structure allows PBDs to bind to the minor groove of DNA, causing DNA damage and cell death.

Mechanism of Action

Pyrrolobenzodiazepines exert their cytotoxic effects by binding to DNA and causing damage. They bind to the minor groove of DNA, forming covalent bonds with the DNA molecule. This binding distorts the DNA structure and prevents the normal functioning of the DNA. This leads to cell death and has a potent effect against rapidly dividing cells, such as cancer cells.

Therapeutic Use

Pyrrolobenzodiazepines have been studied for their potential use in cancer therapy. They are often used as the cytotoxic component in antibody-drug conjugates (ADCs), which are a type of targeted cancer therapy. ADCs use antibodies to deliver cytotoxic drugs directly to cancer cells, reducing the side effects associated with traditional chemotherapy.

See Also

• Antibiotics
• Antibody-drug conjugates
• DNA damage
• Cancer therapy

Resources

Latest articles - Pyrrolobenzodiazepine

• Most recent articles
• Ongoing trials

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Pyrrolobenzodiazepine for any updates.

‎